Agenus Inc. — 2011 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2011; the filing was signed March 6, 2012. This is an annual report, not a standalone fourth-quarter filing. Unless noted otherwise, amounts are U.S. dollars.
Business context
Agenus is a clinical-stage biotechnology company developing cancer and infectious-disease immunotherapies. Its main platforms are QS-21, a vaccine adjuvant licensed to third parties, and heat shock protein technologies, including the Prophage cancer vaccines and HerpV. Oncophage was approved in Russia for certain kidney cancer patients; other internally developed candidates remained investigational.
Financial performance and liquidity
| Metric | 2011 | 2010 |
|---|---|---|
| Revenue | $2.76 million | $3.36 million |
| Research and development expense | $11.02 million | $12.88 million |
| General and administrative expense | $10.82 million | $12.11 million |
| Operating loss | $19.09 million | $21.75 million |
| Net loss | $23.28 million | $21.91 million |
| Net loss attributable to common stockholders | $24.07 million | $22.70 million |
| Operating cash used | $16.25 million | $14.76 million |
| Cash and cash equivalents at year-end | $10.75 million | $19.78 million |
- Revenue fell about 18%; 2011 revenue consisted of research-and-development revenue, with no product or grant revenue reported. The filing does not provide a meaningful product gross margin.
- Operating expenses declined, but net loss increased as 2010 included $4.68 million of non-operating income, principally debt-extinguishment and derivative fair-value gains; 2011 non-operating income was negligible.
- Year-end current assets were $12.00 million and current liabilities $4.75 million. Stockholders’ deficit was $20.83 million.
- Debt principal outstanding was approximately $37.9 million, predominantly $37.5 million of 8% secured convertible notes due August 2014. The 2011 cash-flow statement shows $7.98 million net proceeds from equity sales and $7.24 million net cash from financing activities.
- Fourth-quarter 2011 revenue was $644,000 and net loss was $6.02 million; loss attributable to common stockholders was $6.22 million, or $0.29 per share.
Material changes and notable items
- R&D expense declined 15% and G&A expense declined 11% from 2010, reflecting program status and cost containment.
- Cash fell by $9.03 million during 2011. Operating cash use increased from 2010 despite the lower reported net loss in 2010 being affected by noncash and one-time items.
- In December 2011, Agenus licensed Oncophage manufacturing, marketing, and development rights in Russia and certain CIS countries to NewVac. The agreement provides for supply payments, modest milestones, and low-double-digit royalties, but NewVac may terminate without cause and commercial sales had been minimal.
- In February 2011, the 2006 notes’ maturity was extended to August 2014 and conversion into Agenus common stock was removed; the notes remain secured by the subsidiary holding QS-21 and HerpV rights.
- A one-for-six reverse stock split took effect in October 2011, after Nasdaq bid-price noncompliance; the company subsequently regained compliance.
Outlook, risks, and contingencies
- Management estimated 2012 annual cash use of $13–16 million and said year-end resources, post-year-end equity and license proceeds, and expected agreement proceeds should fund operations into 2013. This is dependent on estimates and future funding; it is not assurance of financing availability.
- Management expected to seek additional capital through licensing, asset sales, debt, or equity, and warned that unavailable or unfavorable financing could force program delays, reductions, or operational cuts.
- The company expected first commercial products containing QS-21 around 2013–2014, subject to partner-led development and regulatory approval. Approximately 15 partner vaccines were in clinical development, including four in Phase 3. Agenus receives no clinical development costs for these partnered products and future royalties are uncertain.
- HerpV Phase 2 was planned for the second half of 2012. Prophage G-100 and G-200 were in Phase 2 glioma trials. The prior Phase 3 Oncophage RCC trial missed its primary endpoint in the overall population; the FDA indicated that trial alone could not support a U.S. filing, and the EMA had issued a negative opinion on the prior application.
- Key risks include recurring losses, dependence on external financing and licensees, clinical and regulatory uncertainty, manufacturing and patient-specific logistics, limited reimbursement prospects, competition, and the 2014 secured-note obligation. The 2006 notes carry restrictive provisions and potential rights over the subsidiary holding QS-21 and HerpV.
- Subsequent to year-end, Agenus reported approximately $18 million in net proceeds from equity offerings and license agreements. On March 2, 2012, it agreed to a $9 million nonrefundable GSK payment, including $2.5 million creditable against future royalties, and granted GSK a five-year first right to negotiate for the company or certain assets. It also reported $6.3 million from licensing non-core technologies and entered a new ATM agreement allowing sales of up to 5 million shares. These post-year-end transactions are not 2011 revenue or year-end cash.
- KPMG gave an unqualified opinion on the financial statements and internal controls. Management reported effective disclosure controls and internal control over financial reporting as of year-end. The IPO-related class action settlement was insurance-funded, with no Agenus financial liability; the filing did not identify other proceedings expected to materially affect the company.
Important facts for investors to verify
- Whether post-year-end proceeds and operating cash use support the stated runway into 2013, and the terms and realized proceeds of subsequent equity issuance.
- The current balance, interest and repayment terms, collateral, and any conversion or subsidiary-equity rights associated with the $37.5 million 2006 notes.
- NewVac’s progress establishing manufacturing and obtaining reimbursement, and whether the Oncophage license produces meaningful sales, milestones, or royalties.
- Clinical and regulatory updates for QS-21 partner programs, Prophage glioma trials, and HerpV, including whether expected development timelines were met.
- The GSK agreement’s full economics and practical effect of its first right to negotiate, including any undisclosed indication royalty terms.
- Potential dilution from the ATM facility, outstanding warrants and options, convertible preferred stock, and other registered shares available for sale.